The Efficacy And Safety Of Infliximab In The Treatment Of Inflammatory Bowel Disease: A Meta-analysis

Objective: To evaluate the efficacy and security of infliximab for inflammatorybowel disease(IBD).Methods: We searched CENTRAL (Cochrane library), MEDLINE(PubMed、OVID),EMBASE and other websites comprehensively. The end points were clinicalremission、clinical remission response and mucosal healing.Results: Of sixty-two articles researched,20randomized controlled trials met thecriteria were included in this meta-analysis. These TCRs included different doses ofIFX versus other different drugs for CD and UC. The analysis showed that IFX wasmore effective than placebo in a long-term clinical remission(RR2.54,95%CI1.69～3.83) and clinical response(RR2.44,95%CI1.75～3.40) for European or AmericanCD patients, and in clinical remission(RR1.52,95%CI1.26～1.85) and mucosalhealing(RR2.97,95%CI1.74～5.08) for Asian CD patients in an eight-weekfollow-up. IFX had no more events compared to placebo for CD patients(RR0.32,95%CI0.00～123.39). IFX was also more effective than placebo in short-termclinical remission(RR3.50,95%CI2.35～5.23) for European or American UCpatients, and a long-term clinical remission(RR2.07,95%CI1.12～3.83) for AsianUC patients. IFX had no more events compared to placebo for UC patients(RR1.06,95%CI0.97～1.5).Conclusions: IFX was effective for long-term clinical remission in Asian、Europeanand American CD patients, and also effective for long-term clinical remission inAsian UC patients. However, it only showed an efficacy of short-term clinicalremission for European and American UC patients. Serious adverse eventsattributable to infliximab were not common in the included studies.